NysnoBio

Executive Summary

NysnoBio is a privately held biotechnology company headquartered in Cambridge, Massachusetts, dedicated to unlocking the therapeutic potential of the Parkin enzyme for precision medicine. Founded in 2018, the company is pioneering gene therapies for Parkinson's disease by targeting patients with specific genetic mutations in the Parkin gene. Its approach aims to restore normal mitochondrial function and protect dopamine neurons, addressing a root cause of Parkinson's rather than just managing symptoms. By focusing on a well-defined genetic subset, NysnoBio seeks to improve clinical outcomes and potentially halt disease progression. The company's lead program is in preclinical development, leveraging a gene therapy modality that delivers a functional copy of the Parkin gene to affected neurons. With a strong scientific foundation and a clear unmet need in Parkin-mutant Parkinson's disease, NysnoBio is positioned to advance a novel therapeutic option tailored to this patient population. The company's progress is closely watched by investors and researchers interested in precision gene therapy for neurodegenerative disorders.

Upcoming Catalysts (preview)

• H2 2026IND Submission for Leading Gene Therapy Candidate40% success
• Q2 2026FDA Orphan Drug Designation70% success
• H1 2026Preclinical Efficacy Data Presentation at Major Conference80% success